Sanofi (NYSE: SNY) reported Q3 EPS of EUR1.47, EUR0.01 better than the analyst estimate of EUR1.46. Revenue for the quarter came in at EUR8.78 billion.

On diabetes, the company said, "Third-quarter sales of the Diabetes division reached €1,799 million, an increase of 8.3%. Year-to-date sales of the Diabetes division increased 12.5% to €5,249 million. Lantus® sales increased 8.1% to €1,567 million in the third quarter. In the U.S., third-quarter sales of Lantus® reached €1,042 million, an increase of 5.8%, reflecting increasing competitive pressure at the payor level. Lantus® SoloSTAR® represented 62.2% of total Lantus® sales, versus 57.4% for the same period in 2013. In Emerging Markets, Lantus® sales grew 19.7% to €232 million in the third quarter, reflecting good performance in China, Turkey, Middle East, Mexico and Africa. In Western Europe, sales of Lantus® recorded a strong performance with sales up 9.5% to €222 million driven by Germany, France and Italy. Year-to-date sales of Lantus® reached €4,572 million, up 12.5%."

"Sanofi has recently concluded payor negotiations in the U.S. and has secured favorable formulary positions for Lantus® with key payors. The level of rebates required to maintain these positions has increased significantly due to aggressive discounting by competitors. The rebates will not change the Group's Business EPS guidance for 2014. The increased rebates in the U.S. and the impact of the Affordable Care Act will continue in 2015. Sanofi expects to mitigate this impact on the Diabetes division in 2015 through the launches of Toujeo® and Afrezza® as well as continued strong growth in Emerging Markets. Therefore, global sales of the Diabetes division are expected to be broadly stable in 2015."

For earnings history and earnings-related data on Sanofi (SNY) click here.